Oncopeptides AB (ONCO)

Currency in SEK
3.970
+0.135(+3.52%)
Real-time Data·
ONCO Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
ONCO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.7204.035
52 wk Range
1.1004.855
Key Statistics
Prev. Close
3.835
Open
3.88
Day's Range
3.72-4.035
52 wk Range
1.1-4.855
Volume
2.51M
Average Volume (3m)
2.57M
1-Year Change
51.28%
Book Value / Share
-0.03
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ONCO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.733
Downside
-31.15%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Oncopeptides AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Oncopeptides AB Company Profile

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells. It offers OPD5, OPDC3, and Gliopep for the treatment of hematological or solid tumors, and glioblastoma. The company also provides Small Polypeptide based Killer Engagers (SPiKE) platform that is designed to bind to both NK-cells and specific targets on various cancer cells. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.

Oncopeptides AB Earnings Call Summary for Q1/2025

  • Net sales surged 161% YoY to SEK 13.3M in Q1 2025, with 34% QoQ growth, driven by Pepaxi's success in European markets
  • Company targets cash flow positivity by end of 2026; exploring Japanese market entry and potential US reentry for growth
  • Stock declined 1.78% pre-market despite strong sales, reflecting investor concerns about future earnings and market challenges
  • CEO Sofia Heagis: '2025 is one of our most transformative years yet'; CFO confirms cash position sustainable until cash flow positive
  • Analysts focused on growth trajectory in different markets, potential currency impacts, and funding options including Japan licensing deal
Last Updated: 15/05/2025, 08:46
Read Full Transcript

Compare ONCO to Peers and Sector

Metrics to compare
ONCO
Peers
Sector
Relationship
P/E Ratio
−3.2x−3.2x−0.5x
PEG Ratio
−0.06−0.050.00
Price/Book
−149.9x8.2x2.6x
Price / LTM Sales
22.0x15.2x3.2x
Upside (Analyst Target)
−46.2%19.6%44.1%
Fair Value Upside
Unlock4.5%6.2%Unlock

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 2.733
(-31.15% Downside)

Earnings

Latest Release
May 16, 2025
EPS / Forecast
-0.29 / --
Revenue / Forecast
13.27M / 18.00M
EPS Revisions
Last 90 days

ONCO Income Statement

People Also Watch

836.40
EVOG
+0.50%
19.95
HTRO
-1.02%
199.0000
BIOAb
+1.53%
124.91
CRWV
+1.54%
45.00
OVZON
-0.66%

FAQ

What Stock Exchange Does Oncopeptides Trade On?

Oncopeptides is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Oncopeptides?

The stock symbol for Oncopeptides is "ONCO."

What Is the Oncopeptides Market Cap?

As of today, Oncopeptides market cap is 896.26M.

What Is Oncopeptides's Earnings Per Share (TTM)?

The Oncopeptides EPS (TTM) is -1.41.

When Is the Next Oncopeptides Earnings Date?

Oncopeptides will release its next earnings report on 20 Aug 2025.

From a Technical Analysis Perspective, Is ONCO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Oncopeptides Stock Split?

Oncopeptides has split 0 times.

How Many Employees Does Oncopeptides Have?

Oncopeptides has 75 employees.

What is the current trading status of Oncopeptides (ONCO)?

As of 22 Jul 2025, Oncopeptides (ONCO) is trading at a price of 3.97, with a previous close of 3.84. The stock has fluctuated within a day range of 3.72 to 4.04, while its 52-week range spans from 1.10 to 4.86.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.